Viatris to Unveil MR-141 0.75% VEGA-3 and LYNX-2 Phase 3 Data at ASCRS Meeting
Viatris will present four abstracts at the April 10–13 ASCRS Annual Meeting, including full Phase 3 VEGA-3 results for MR-141 (phentolamine 0.75%) in presbyopia and the Phase 3 LYNX-2 study of MR-142 for low-light visual disturbances post-refractive surgery. Also includes Phase 1 varenicline spray data and a MIRA-2 analysis of RYZUMVI® for mydriasis reversal.
1. ASCRS Meeting Participation
Viatris will present four scientific abstracts at the American Society of Cataract and Refractive Surgery Annual Meeting in Washington, D.C., April 10–13, 2026. The company also provided an educational grant for a continuing medical education symposium on pharmacological vision correction and will be available at booth #233.
2. Highlighted Phase 3 Clinical Studies
The presentations include full Phase 3 VEGA-3 results for MR-141 (phentolamine ophthalmic solution 0.75%) evaluating presbyopia and the Phase 3 LYNX-2 trial of MR-142 assessing mesopic visual disturbances in post-refractive surgery patients. A post-hoc analysis of the MIRA-2 study will detail RYZUMVI®’s optical impact for reversing pharmacologically induced mydriasis.
3. Early-Stage Data and Strategic Outlook
Additional sessions feature Phase 1 varenicline solution nasal spray data in healthy adults and underscore Viatris’s global licensing agreement with Opus Genetics, granting exclusive U.S. commercialization rights for phentolamine ophthalmic solution 0.75%. These developments reinforce the company’s strategic focus on its innovative ophthalmology portfolio.